Curative Biosciences Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	2009 - 2012
Period Ending	Mar '18 Mar 31, 2018	Jun '17 Jun 30, 2017	Jun '16 Jun 30, 2016	Jun '15 Jun 30, 2015	Jun '14 Jun 30, 2014	Jun '13 Jun 30, 2013	2009 - 2012
Revenue	-	-	-	-	-	0.16	Upgrade
Revenue Growth (YoY)	-	-	-	-	-	-48.58%	Upgrade
Cost of Revenue	-	-	-	-	0.05	0.11	Upgrade
Gross Profit	-	-	-	-	-0.05	0.06	Upgrade
Selling, General & Admin	0.11	0.05	1.59	1.7	0.37	0.89	Upgrade
Research & Development	-	-	0.05	-	-	-	Upgrade
Operating Expenses	0.52	0.05	1.64	1.71	0.42	0.89	Upgrade
Operating Income	-0.52	-0.05	-1.64	-1.71	-0.47	-0.84	Upgrade
EBT Excluding Unusual Items	-0.52	-0.05	-1.64	-1.71	-0.47	-0.84	Upgrade
Legal Settlements	-	-	-	-0.2	-0.18	-	Upgrade
Other Unusual Items	-	-	-0.02	-1.46	-29.35	-5.8	Upgrade
Pretax Income	-0.52	-0.05	-1.66	-3.37	-30	-6.64	Upgrade
Net Income	-0.52	-0.05	-1.66	-3.37	-30	-6.64	Upgrade
Net Income to Common	-0.52	-0.05	-1.66	-3.37	-30	-6.64	Upgrade
Shares Outstanding (Basic)	17	16	14	8	4	0	Upgrade
Shares Outstanding (Diluted)	17	16	14	8	4	0	Upgrade
Shares Change (YoY)	6.97%	12.77%	82.50%	106.23%	6728.01%	322.64%	Upgrade
EPS (Basic)	-0.03	-0.00	-0.12	-0.44	-8.11	-122.47	Upgrade
EPS (Diluted)	-0.03	-0.00	-0.12	-0.44	-8.11	-122.47	Upgrade
Free Cash Flow	-0.08	-0.01	-0.03	-0.07	-0.14	-0.16	Upgrade
Free Cash Flow Per Share	-0.01	-0.00	-0.00	-0.01	-0.04	-2.91	Upgrade
Gross Margin	-	-	-	-	-	34.75%	Upgrade
Operating Margin	-	-	-	-	-	-517.62%	Upgrade
Profit Margin	-	-	-	-	-	-4098.57%	Upgrade
Free Cash Flow Margin	-	-	-	-	-	-97.47%	Upgrade
EBITDA	-0.52	-0.05	-1.64	-1.7	-0.43	-0.84	Upgrade
D&A For EBITDA	0	0	0	0	0.04	0	Upgrade
EBIT	-0.52	-0.05	-1.64	-1.71	-0.47	-0.84	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.